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Engineering Src family protein kinases with unnatural nucleotide 
specificity 
Yi Liu 1, Kavita Shah 1, Feng Yang 1, Laurie Witucki 1 and Kevan M Shokat 1,2 
Background: Protein kinases play a central role in controlling diverse signal 
transduction pathways in all cells. The identification of the direct cellular 
substrates of individual protein kinases remains the key challenge in the field. 
Results: We describe the protein engineering of v-Src to produce a kinase 
which preferentially uses an ATP analog, N6-(benzyl) ATP, as a substrate, rather 
than the natural v-Src substrate, ATP. The sidechain of a single residue (11e338) 
controls specificity for NB-substituted ATP analogs in the binding pocket of 
v-Src. Elimination of this sidechain by mutation to glycine produces a v-Src 
kinase which preferentially utilizes NS-(benzyl) ATP as a phosphodonor 
substrate. Our engineering strategy is generally applicable to the Src family 
kinases: mutation of the corresponding residue (Thr339 to glycine) in the Fyn 
kinase confers specificity for N6-(benzyl) ATP on Fyn. 
Condusions: The v-Src tyrosine kinase has been engineered to exhibit 
specificity for an unnatural ATP analog, N6-(benzyl) ATP, even in a cellular 
context where high concentrations of natural ATP are present (1-5 mM), where 
preferential use of the ATP analog by the mutant kinase is essential. The mutant 
v-Src transfers phosphate more efficiently with the designed unnatural analog 
than with ATP. As the identical mutation in the Src-family kinase Fyn confers on 
Fyn the ability to recognize the same unnatural ATP analog, our strategy is likely 
to be generally applicable to other protein kinases and may help to identify the 
direct targets of specific kinases. 
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I n t roduct ion  
Protein kinases catalyze the transfer of the y phosphate 
from ATP to serine, threonine, tyrosine, or histidine resi- 
dues of protein substrates. They are found in many cellu- 
lar compartments, in membranes, the cytosol, associated 
with the cytoskeleton or in the nucleus, and are involved 
in a wide variety of cellular functions, including cytokine 
responses, antigen-dependent immune responses, regula- 
tion of the cell cycle, modification of cell morphology, 
learning and memory, ion-channel regulation and stress 
responses (to ultraviolet light and oxidants) [1]. Kinase 
involvement in these diverse pathways makes the super- 
family of protein kinases a large and important class of 
enzymes in cellular signal transduction. The first tyro- 
sine kinase to be identified was v-Src, which is responsi- 
ble for the transformation of fibroblasts by the Rous 
sarcoma virus (RSV) [21. The origin [31, regulation 
[1,4-6] and structure of v-Src [7-9], as well as of its cellu- 
lar homolog c-Src [10-11], have been studied extensively 
and are well understood. The two kinases differ in 
several respects; many v-Src isolates contain a carboxy- 
terminal deletion which results in the loss of the 
inhibitory Tyr527. Another frequent mutation to the 
c-Src gene is found at position 338 where isoleucine is 
substituted for Thr338. The carboxy-terminal deletion or 
the Thr338---~Ile mutation are individually sufficient, but 
not necessary, for transforming activity of v-Src. The 
latter mutation alone results in a v-Src gene which is only 
partially transforming [12]. 
The v-Src kinase is highly active. Over 50 proteins become 
phosphorylated (either directly or indirectly) by v-Src upon 
RSV infection of fibroblasts [13]. Although v-Src has been 
intensely studied using almost every biochemical and 
genetic tool available, we still do not know whether many 
of these 50 proteins are direct v-Src targets or are targets of 
intermediary kinases [14]. Identification of the specific 
substrates of all protein tyrosine kinases is made difficult 
by the large number of cellular kinases (it is estimated that 
2% of the mammalian genome encodes protein kinases 
[15]), by the overlapping target specificity displayed by 
tyrosine kinases [1-11,13-16], and by the very low abun- 
dance of phosphotyrosine (only 0.03% of cellular phospho- 
aminoacids are phosphotyrosine [17]). 
We previously reported a protein-engineering-based 
method for identifying the direct substrates of v-Src [18]. 
To differentiate the cellular substrates of v-Src from all 
other kinase substrates, we mutated the ATP-binding 
site of v-Src such that the engineered kinase uniquely 
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Table 1 
Kinetic constants for phosphorylaUon of the IYGEFKKK peptlde by wild-type and mutant v.Src kinases, 
GST-XD4 (wild-type v-Src) GST-XD4 (1338A) 
kcat Krn I~at/Kr. kcat Km 
Nucleotide (rain -1) (!LtM) (min -1 M -1) (min "1) (IxM) 
GST-XD4 (1338G) 
Iqat/Kr~ kcat Kr. kcat/Km 
(rain-1 M-l) (rain-l) (l.tM) (min -1 M-l) 
ATP 9+0.5  12_+3 1.6x 10 s 1 _+0.3 70_+10 
N6-(cyclopentyl) ATP > 9000 (Ki) (2.5 -1- 1) × 10 -2 40+ 10 
NS-(benzyl) ATP > 2000 (K i) 0.5 + 0.2 20 _+ 4 
1.4+104 0.8+0.3 80:t:10 1 x l04 
6.2--102 0.1+0.05 15-1-3 6.7x103 
2,5×104 0.2+0,1 5+2 4.0x 104 
Kinetic constants were measured at low substrate conversion (< 5°/0) in triplicate and were determined by analysis of Lineweaver-Burk plots of the 
rate data. Reactions were performed in the same manner as in Figure 3 except for substitution of [7-32P] ATP by [y.32p] N6.(cyclopentyl) ATP or 
[7-32P] NS-(benzyl) ATP (both 5000 cpm/pmol) as indicated, K i is the inhibition constant for the individual analog. 
accepted a synthetic N6-substituted ATP analog (A*TP; 
N6-(cyclopentyl) ATP. The mutant v-Src was designed 
with four criteria in mind: it should be able to accept an 
ATP analog that is orthogonal (i.e., not a substrate for 
any wild-type protein kinase); it should use the A*TP 
with high catalytic efficiency; it should exhibit reduced 
catalytic efficiency with ATP, so that [~/_3zp] A*TP is the 
preferred substrate in the cellular milieu where ATP is 
present at high concentrations; and it should have the 
same substrate specificity as nonengineered ('wild type') 
v-Src. Initially, we identified two residues (Va1323 and 
I1e338) in the v-Src catalytic domain which appeared to 
control specificity for N6-substituted ATP analogs. 
Alanine mutagenesis of both residues (Va1323---~Ala, 
V323A and Ile338~Ala, I338A) in a v-Src fusion protein, 
GST-XD4 (V323A, I338A), produced akinase capable of 
accepting an ATP analog, N6-(cyclopentyl) ATP, which 
is not accepted by wild-type kinases. The engineered 
double-alanine mutant of v-Src in combination with 
N6-(cyclopentyl) ATP satisfied three of our four design 
criteria, but only partially satisfied the requirement for 
preferential use of A*TP. The catalytic efficiency of the 
doubly mutated kinase with N6-(cyclopentyl) ATP 
(kcat/K M = 3.3× 103 min -1 M -1 [18]) was comparable to the 
efficiency of the mutant with ATP (kcat/KM= 
5.3 × 103 min -1 M -1 [18]), but was significantly lower 
than the efficiency of the wild-type v-Src with ATP 
(kcat/K M = 1.6 × 105 rain -1 M-l; Table 1). 
The 50-fold lower efficiency of mutant v-Src (V323A, 
I338A) with N6-(cyclopentyl) ATP compared to the wild- 
type kinase could be considered a success in terms of 
engineering novel enzyme specificity. Our goal, however, 
was to design a mutant kinase capable of competing with 
wild-type kinases in a cellular context, and thus the 
mutant kinase is required to display close to wild-type cat- 
alytic efficiency with the unnatural triphosphate. If this 
design criterion is not adequately satisfied, the targets of 
mutant v-Src will be only minimally phosphorylated in the 
presence of active wild-type kinases and ATP. In fact, 
when we attempted to radiolabel direct substrates of v-Src 
(V323A, I338A) using the doubly mutated v-Src and 
[7--3zP] N6-(cyclopentyl) ATP, we observed suboptimal 
labeling of v-Src's substrates because of competition 
between wild-type kinases and the less active mutant 
kinase for N6-(cyclopentyl) ATP (K.S., Y.L. and K.M.S., 
unpublished observations). To overcome this problem, we 
sought to re-engineer v-Src, as well as search for new 
analogs of ATP, in order to enhance the catalytic activity 
of the mutant v-Src with A*TPs. 
Here we report a site-directed mutagenesis tudy of 
residues in the v-Src active site which contact the N 6 
amine of ATP. The mutant v-Src proteins were tested as 
catalysts of peptide and protein phosphorylation using a 
variety of synthetic ATPs (A*TPs). After identification of 
the 'best match' between a v-Src mutant and an A*TP, 
we examined the general applicability of our strategy by 
mutagenizing the Src-related tyrosine kinase Fyn, which 
shares 85% sequence identity with v-Src. We show that 
the mutational strategy can be extended to other Src 
family kinases and, by further sequence comparisons, to 
other kinase families as well. 
Resu l ts  and  d iscuss ion  
Ile338 controls specificity for N6-substltuted ATP analogs 
We previously showed that ATP analogs with N 6 sub- 
stituents larger than an isopropoxy group are not accepted 
by wild-type protein kinases [18]. At that time there were 
no crystal structures of tyrosine kinases in an active con- 
formation [19-21], so it was not easy to determine the 
residue(s) responsible for limiting the steric bulk of N 6 
substituents on ATP. Inspection of the crystal structures 
of the serine/threonine kinases (cAMP-dependent kinase, 
PKA [21] and the cyclin-dependent kinase CDK2 [22]) in 
the region around the N 6 amine of bound ATP revealed 
two amino acid sidechains within 5~ of the N 6 amino 
group of ATP. Mutation of the corresponding residues in 
v-Src to the less sterically demanding residue alanine 
afforded a protein kinase which utilized ATP analogs 
with bulky N 6 substituents, in agreement with our pre- 
dictions from homology modeling (shown in [18]). 
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Figure 1 
Surface representation of the ATP-binding pocket in three distantly 
related protein kinases: the Src family member Hck, PKA, and CDK2. 
The solvent-accessible surface of each kinase within 7 A of ATP is 
shown in white mesh, and the surface of ATP is shown in blue mesh. 
(a) Wild-type Hck + AMP-PNP. The portion of Hck's solvent- 
accessible surface area formed by Thr338 (corresponding to Ile338 in 
v-Src) is shown in red mesh and the portion of the surface formed by 
Val323 is shown in green mesh. (b) Wild-type PKA + ATP. The portion 
of PKA's solvent-accessible surface ares formed by Met120 
(corresponding to Ile338 in v-Src) is shown in red mesh and the 
portion of the surface formed by Vail 04 is shown in green mesh. 
(c) Wild-type CDK2 + ATP. The portion of CDK2's solvent-accessible 
surface area formed by Phe80 (corresponding to Ile338 in v-Src) is 
shown in red mesh and the portion of the surface formed by Va164 is 
shown in green mesh. ATP, and the residues corresponding to Ile338 
and Val323 in v-Src in each kinase (a-c) are shown in stick 
representation with the following atom coloring: O, red; N, blue; C, 
white; P, yellow. These figures were created using the molecular 
modelling program GRASP [41]. 
Recently, structures of three Src-family kinases (c-Src 
[11], Hck [23], and Lck [24]) have made possible a more 
detailed analysis of the similarities between the two fami- 
lies of kinases (serine/threonine and tyrosine kinases) 
with respect o the pocket around the N 6 amine of ATP. 
The ATP-binding pockets of the three distantly related 
kinases are shown in Figure 1 in surface representation. 
We analyzed the kinase active sites, looking for a con- 
served structural feature which could explain the inability 
of wild-type kinases to accept N6-substituted ATP 
analogs. It was immediately apparent that the shape com- 
plementarity between the kinase active site and the N 1 
and N 6 positions of the ATP purine ring is well conserved 
in all three kinases. In particular, there is little unoccu- 
pied space adjacent to the N 6 amine of ATP in any of the 
available kinase crystal structures. 
We next turned to sequence alignments of all protein 
kinases to identify conserved residues which would be 
responsible for forming the complementary interactions 
with the N 6 position of ATP in all kinases. Surprisingly, 
analysis of kinase sequence alignments indicated hat the 
two residues which make close contact with the N 6 amine 
of ATP (Va1323, I1e338 in v-Src) are not completely con- 
served in all kinases, as the three-dimensional structures 
might have suggested (Figure 2). Although the residue 
that corresponds to Va1323 in v-Src is most often a 
I~-branched residue (a residue which contains two non- 
hydrogen atoms at the 13 carbon), it can also be a small 
unbranched residue, such as alanine (see Figure 2, red 
letters). The fact that several kinases contain alanine at 
this position suggested to us that this residue might not be 
responsible for limiting the steric bulk of N 6 substituents 
on ATP. We also analyzed the crystal structures of Hck, 
PKA, and CDK2 in terms of the importance of residues 
that correspond to Va1323 of v-Src in forming the pocket 
around the N 6 position of ATP. The surface formed by 
Va1323 in Hck is colored in green mesh (Figure la). Only a 
small patch of green is visible because Va1323 does not sig- 
nificantly contribute to forming the N6-binding pocket of 
Hck. Similarly, the residue that corresponds to Va1323 in 
PKA (Vail04, green surface in Figure lb) does not con- 
tribute to the ATP-binding pocket in PKA. Interestingly, 
by contrast, the corresponding residue in CDK2, Va164 
(green mesh in Figure lc), does contribute significantly to 
the N6-binding pocket in this kinase. 
The other residue in the vicinity of the N 6 group that 
corresponds to Thr338 in c-Src (see Figure 2; interest- 
ingly, this residue is mutated to isoleucine in some v-Src 
isolates, see below) is quite structurally conserved across 
the kinase family in that no kinases contain small 
unbranched alanine or glycine residues at this position 
(Figure 2). In fact, the smallest residue in any kinase at 
this position is serine (Figure 2, purple S). Structural 
comparison of the contribution of this residue to the 
N6-binding pocket of ATP in the three kinases analyzed 
(shown in red mesh, Figure 1) confirms that a significant 
portion of the ATP-binding pocket in the region around 
the N 6 amine is formed by this single residue. On the 
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Figure 2 
Subdomain:  
v-Src residue: 
v-  SRC 
c -SRC 
PKA 
PKG - 1 
cPKC-~ 
~ARK1 
S6K 
RSKI  
CaMK2 
Cdk2 
Erk2  
GSK3~ 
Cdc7  
Cot  
MEKI  
S te7  
Ste l l  
Nek l  
N IMA 
Fused  
N inaC 
Cdc l5  
Npr l  
Wee l  
CK Ia  
Pkn l  
ZmPKI  
Mos  
IV  V 
323  338  
RHEKLVQLYAVVSE . . . . . . . . . .  EP IY IV IEYMSK 
RHEKLVQLYAVVSE . . . . . . . . . .  EP IYTV IEYMSK 
NFPFLVKLEFSFKDN . . . . . . . . .  SNL~YVPG 
HSDFIVRLYRTFKDS . . . . . . . . .  KYLYMLMEACLG 
KPPFLTQLHSCFQTV . . . . . . . . .  DRLYFVMEYVNG 
DCPF IVCMSYAFHTP . . . . . . . . .  DKLSF ILDLMNG 
KHPF IVDL IYAFQTG . . . . . . . . .  GKLYL ILEYLSG 
NHPFVVKLHYAFQTE . . . . . . . . .  GKLYL ILDFLRG 
KHPNIVRLHDSISEE  . . . . . . . . .  GHHYL IFDLVTG 
NHPNIVKLLDVIHTE . . . . . . . . .  NKLYLVFEFLHQ 
RHENI IG INDI IRAPT IEQM . . . .  QDVYIVQDLMET 
DHCNIVRLRYFFYSSGEKKDE- - -LYLNLV~EYVPE 
GSSRVAPLCDAKRVR . . . . . . . . .  DQVIAVLPVVPH 
RHENIAELYGALVWG . . . . . . . . .  ETVHLFMEAGEG 
NSPY IVGFYGAFYSD . . . . . . . . .  GE IS ICMEHMDG 
PHENI ITFYGAYYNQHIN . . . . . .  NE I I I LMEYSDC 
HHENIVTYYGASQEG . . . . . . . . .  GNLNIFLEYVPG 
KHPNIVQYKESFEEN . . . . . . . . .  GSLY IVMTYCEG 
RHPNIVAYYHREHLKAS . . . . . . .  QDLYLYMEYCGG 
KHPHVIEMIESFESK . . . . . . . . .  TDLFV IP~EFALN 
DHPNLPEFYGVYKLSKPNGP . . . .  DE I~YCHE 
NHNNIVKYHGFTRKS . . . . . . . . .  YELY IL IEYCAN 
NHPNI IET IEV IYNE . . . . . . . . .  DR ILQVMEYCEY 
QHSHVVRYFSAWAED . . . . . . . . .  DHMLIQNEYCNG 
GGVGIPHIRWYGQEK . . . . . . . . .  DYNVLVMDLLG 
GHENIVS IFDMDATP . . . . . . . . .  PRPYL IMEFLD 
NHMNLVRIWGFCSEG . . . . . . . . .  SHRLLVSEYVEN 
RHDNILALYGYSIKG . . . . . . . . .  GKPCLVYQLMKG 
Chemist~&Biology 
Sequence alignment of subdomains IV and V of representative protein 
kinases from the protein kinase sup erfamily of Hanks and Quinn [42]. 
Residues predicted to be within 5 A of the N s amine of bound ATP 
(Val323 and Ile338, v-Src numbering) are shown in bold. At least two 
protein kinases, Cot and CdcT, naturally contain residues with small 
sidechains - alanine in both cases, highlighted in red - at the position 
that corresponds to position 323 in v-Src. The smallest naturally 
occurring residue at position 338 in the databank is serine (shown in 
purple, in ZmPK1). 
basis of these structural and sequence alignment analyses, 
we propose that the single bulky residue at the position 
corresponding to Ile338 in v-Src in most if not all kinases 
is primarily responsible for restricting the ability of wild- 
type kinases to accept N 6- substituted ATP analogs. 
Although structural and sequence analyses provide good 
starting points for designing novel enzyme properties, an 
optimal design usually requires an iterative process of 
mutation, kinetic analysis, and further structural analysis 
[25]. In order to explore the pocket dimensions and 
geometries ofour mutant v-Src (V323A, I338A) more fully, 
we asked whether mutation of residue 338 and not residue 
323 was necessary and sufficient for v-Src to accept bulky 
ATP analogs. We used site-directed mutagenesis to con- 
struct single mutants of v-Src, GST-XD4 (V323A), and 
GST-XD4 (I338A) and evaluated their binding affinity 
for the A*TPs shown in Figure 3b. The A*TPs were 
tested as inhibitors of [7-3zP] ATP-dependent phosphory- 
lation of a peptide substrate (IYGEFKKK; using single 
letter amino-acid code) [16]. The single mutant 
GST-XD4 (V323A) displays almost the same inhibition 
pattern as wild-type v-Src (GST-XD4, Figure 3), suggest- 
ing that mutation of this residue to alanine is not impor- 
tant in enlarging the ATP-binding pocket near the N 6 
amine of ATP. In contrast, phosphorylation by the single 
mutant GST-XD4 (I338A) is inhibited by bulky A*TPs 
(Figure 3), suggesting that residue 338 is what controls 
binding of N6-substituted A*TPs to wild-type v-Src. 
We anticipated that if a single substitution in v-Src 
(I338A) was sufficient o confer A*TP binding, disruption 
of the kinase's active site might be less than in the double 
mutant [18], and so the I338A kinase might display higher 
catalytic efficiency than the double mutant (V323A, 
1338A). The single mutation to v-Src (I338A) however, 
displays the same lower catalytic efficiency with ATP as a 
phosphodonor as is found with the V323A, I338A double 
mutant (Figure 4, lanes 2,4). Interestingly, the single 
mutation to v-Src which does not confer A*'FP binding 
(V323A) shows a catalytic efficiency similar to that of the 
wild-type form of the kinase with ATP (Figure 4, lanes 
1,3). Unfortunately, the V323A mutant does not accept 
N6-(cyclopentyl) ATP as a phosphodonor for autophos- 
phorylation (Figure 4, lane 7), so it does not satisfy all of 
our design requirements. Although we have identified the 
minimal perturbation to the v-Src structure which is suffi- 
cient to confer A*TP binding, the mutation results in a 
twofold loss of catalytic activity (k~ t) when ATP is a sub- 
strate. The space-creating mutation I338A may be remov- 
ing an important interaction with the natural substrate 
ATP in the transition state. 
Plasticity at position 338 
Our alanine scanning mutagenesis study of residues with 
sidechains in the 5 A sphere of the N 6 group in ATP sug- 
gested I1e338 in v-Src controls A*TP specificity. We 
carried out a more focused mutagenesis study at position 
338, in order to search for a mutant hat displays efficient 
A*TP analog binding and high catalytic efficiency. We 
mutated Ile338 to valine, serine, or cysteine to determine 
whether esidues larger than alanine but smaller than the 
isoleucine or threonine found in the wild-type kinases 
would display the desired catalytic activity and A*TP 
binding. These mutants display poor binding affinity for 
large N6-substituted analogs, and their specificity for 
other analogs is essentially like that of the wild-type 
kinase (Figure 5). This analysis suggests that alanine is 
the largest amino acid that can confer A*TP binding on 
v-Src. Moreover, no known kinases (http://www.sdsc. 
edu/kinases/pkr/pk_catalytic/) naturally contain an 
alanine at the position corresponding to Ile338 in v-Src. 
This sequence conservation might be responsible for our 
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Figure 3 
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Chemistry & Biology J 
(a) Evaluation of the binding efficiency of A*TPs to wild-type and 
Val323 and Ile338 mutant v-Src kinases. Binding efficiency was 
determined by inhibiting [7-32P] ATP-dependent phosphorylation of the 
peptide IYGEFKKK by GST-XD4 (wild-type v-Src), GST-XD4 
(V323A), GST-XD4 (V323A, 1338A) and GST-XD4 (1338A) with 
unlabelled ATP and ATP analogs 1-12. Percentage inhibition is 
calculated as (1 - vJv0) where v i is the disintegration rate (cpm) in the 
presence of 100 I.tM of the indicated triphosphate and 10 ~tM [~32p] 
ATP (1000 cpm/pmol) and v 0 is the disintegration rate (cpm) in the 
presence of 10 txM [~.32p] ATP (1000 cpm/pmol) alone. (b) Structures 
of ATP analogs (A*TPs; 1-12) used in this experiment. 
observation that no wild-type kinases are able to accept 
N6-(cyclopentyl) ATP as a substrate [18]. 
The only remaining substitution at position 338 that is 
predicted to allow catalysis with A*TP is glycine, because 
it is smaller than alanine. Indeed, GST-XD4 (I338G) 
shows the same inhibition pattern as that of GST-XD4 
(I338A) with a slightly enhanced binding affinity for the 
analogs containing larger N 6 groups (Figure 5). It there- 
fore appears that residues larger than alanine at position 
338 preclude binding of A*TPs whereas alanine and 
glycine at this position confer on v-Src the ability to bind 
A*TPs that have bulky N 6 substituents. 
Figure 4 
[7"32P] -ATP [7-32P]-A*TP (8) 
I I I I 
1 2 3 4 5 6 7 8 
Chemistry & Biology 
Autoradiograms howing [y-32p]ATP-dependent autophosphorylation of
GST-XD4 (wild-type v-Src), lane 1 ; GST-XD4 (V323A, 1338A), lane 2; 
GST-XD4 (V323A), lane 3; GST-XD4 (1338A) lane 4; and [y.32p] N s- 
(cyclopentyl) ATP-dependent phosphorylation of GST-XD4 (wild-type v- 
Src), lane 5; GST-XD4 (V323A, 1338A), lane 6; GST-XD4 (V323A), 
lane 7; GST-XD4 (1338A), lane 8. The autophosphorylation reaction was 
carried out as described in the Materials and methods ection. 
Structural context of residue 338 
The crystal structure of c-Src shows that Thr338 is at the 
back of the nucleotide-binding pocket in the interdomain 
hinge which links the catalytic amino- and carboxy-termi- 
nal domains [11]. Mutation of v-Src Ile338 to glycine is 
predicted to have two effects on the enzyme - -  enlarge 
the ATP-binding pocket, and lend more flexibility to 
interdomain hinge [26]. We asked which of these two 
effects is more important for conferring A*TP specificity 
on v-Src; we attempted to increase the flexibility of the 
interdomain hinge without enlarging the ATP-binding 
pocket, and asked whether this allowed v-Src to accept 
A*TPs. We focused on residue Glu339 in the hinge, 
because the carboxylate sidechain of Glu339 is oriented 
away from the interior of the ATP-binding site in all exist- 
ing kinase crystal structures; thus its mutation to alanine 
or glycine was not expected to affect the N 6 pocket 
dimensions. Because it is the residue adjacent to I1e338 in 
the interdomain hinge, addition of a glycine residue was 
expected to enhance the flexibility of the hinge to a 
similar extent as in the 1338G mutant. We found that the 
GST-XD4 (E339G) mutant is inhibited to a certain 
extent by N6-substituted ATP analogs, compared with 
wild-type v-Src, but not nearly to the extent found in 
GST-XD4 (I339G). In Figure 6, the I338G mutant shows 
97% inhibition by N6-(cyclopentyloxy) ATP whereas the 
E339G mutant shows only 42% inhibition by the same 
A*TP. This analysis demonstrated that interdomain flexi- 
bility has an effect on A*TP binding, but relief of steric 
congestion in the ATP-binding pocket adjacent o the N 6 
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Figure 5 
..g 
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9 11 A*TPs 12 
T-XD4 (1338G) 
,XD4 (1338A) 
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(W33SC) 
=38V) 
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v-Src kinase 
(11e338 mutants) 
Evaluation of the binding efficiency of A*TPs 
to wild-type and Ile338 mutant v-Src kinases. 
Binding efficiency was determined by 
inhibiting [,y.s2p] ATP-dependent 
phosphorylation of the peptide IYGEFKKK by 
GST-XD4 (wild-type v-Src), GST-XD4 
(1338V), GST-XD4 (1338C), GST-XD4 
(1338S), GST-XD4 (1338A) and GST-XD4 
(1338G) with unlabelled ATP and some of the 
ATP analogs shown in Figure 3b. Percentage 
inhibition was defined in the same manner as 
in Figure 3a. 
amine is the most critical feature for engineering unnat- 
ural ATP analog specificity. 
Determining the optimal ATP analog for 1338A or 1338G 
mutants of v-Src 
Although N6-(cyclopentyl) ATP was identified as the 
optimal substrate for the first-generation double-alanine 
mutant (V323A, I338A) [18], it was not unreasonable to
expect hat each new kinase mutant might exhibit subtle 
differences in the ability to catalyze phosphorylation with 
other A*TPs. Because our analysis of A*TP binding to 
v-Src mutants yielded two new v-Src mutants, I338A and 
I338G, we decided to probe these two new'kinases with 
Figure 6 
all the available A*TPs (Figure 3b) to find the best match 
of unnatural substrate (A*TP) and mutant enzyme. Using 
[T-3zP] ATP as the phosphodonor and an optimal peptide 
substrate (IYGEFKKK), the binding affinity of v-Src 
mutants for A*TPs can be measured using an inhibition 
assay. The disadvantage of such an assay is that analogs 
which have tight binding constants are not necessarily 
good substrates. One solution to this problem is to synthe- 
size [y-3zp]-labeled A*TPs and to test them in a peptide 
phosphorylation assay; this is not very appealing, however, 
as it involves a great deal of radioactive synthesis. We 
chose to use a nonradioactive assay which could irectly 
test nonradiolabeled A*TPs as substrates of mutant 
ATP 1 
Chemistry & Biology 
2 3 
4 5 
A*TPs 
8 9 11 12 
|ST-XD4 (1338G) 
;T-XD4 (E339G) 
• GST-XD4 (E339A) 
GST-XD4 (wild type) 
v-Sre kinase 
(Glu339 mutants) 
Evaluation of the binding efficiency of A*TPs 
to wild-type and Ile338 and Glu339 mutant v- 
Src kinases. Binding efficiency was 
determined by inhibiting [~/.~2p] ATP- 
dependent phosphorylation f the peptide 
IYGEFKKK by GST-XD4 (wild-type v-Src), 
GST-XD4 (1339A), GST-XD4 (E33gG) and 
GST-XD4 (E338G) with unlabelled ATP and 
and some of the ATP analogs shown in Figure 
3b. Percentage inhibition was determined in 
the same manner as in Figure 3a.
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Figure 7 
Control " j~ / ' -  '~'~" 
(no ATP) ATP 5 
XD4 (wild type) 
6 8 9 11 12 
XD4 (1338A) 
XD4 (1338G) 
Chemistry & Biology 
Anti-phosphotyrosine immunoblot of GFP-IYGEF phosphorylation with 
ATP and various ATP analogs by GST-XD4 (wild-type v-Src), 
GST-XD4 (1338A) and GST-XD4 (1338G). Lane 1, control, no ATP; 
lane 2, ATP; lane 3, N6-(benzoyl) ATP (the ATP N6 substitution is 
shown above the lane); lane 4, N6-(benzyl) ATP (5); lane 5, N s- 
(benzyloxy) ATP (6); lane 6, N6-(cyclopentyl) ATP (8); lane 7, N 6- 
(cyclopentyloxy) ATP (9); lane 8, N6-(cyclohexyl) ATP (11); lane 9, N 8- 
(cyclohexyloxy) ATP (12). Reaction conditions are described in the 
Materials and methods section. 
kinases. The best existing nonradioactive assay is a 
coupled ADP-formation assay that uses ADP-requiring 
enzymes, but this cannot be extended to our A*DP prod- 
ucts [27]. We therefore developed a new assay that utilizes 
a highly specific anti-phosphotyrosine antibody to detect 
phosphorylation of a specific tyrosine on an engineered 
substrate (green fluorescent protein carboxy-terminally 
tagged with an optimal Src substrate EIYGEF, designated 
'GFP-IYGEF'; FY., Y.L., SD. Bixby, J.D. Friedman and 
K.M.S., unpublished observations). 
The anti-phosphotyrosine immunoblot of GFP-IYGEF 
phosphorylation by v-Src with orthogonal ATP analogs 
(A*TP analogs not accepted by wild-type kinases) is 
shown in Figure 7. The best substrate for both the I338A 
and I338G mutants is N6-(benzyl) ATP, as measured by 
the intensity of the anti-phosphotyrosine immunoblot 
signal (Figure 7, lane 7). The inhibition assay (Figure 5) 
shows that the I338A and I338G v-Src mutants display 
similar binding affinity with analogs 5, 6, 8, 9, 11, and 12 
(Figure 5), yet the catalytic activity assay demonstrates 
that these two mutants use these ATP analogs with quite 
different catalytic efficiencies. 
The GST-XD4 (I338G) mutant shows the highest inhibi- 
tion with 9, N6-(cyclopentyloxy) ATP, (Figure 5) but this 
analog is not as good a substrate as either N6-(benzyl) 
ATP or N6-(cyclopentyl) ATP (Figure 7, lanes 4 and 6, 
respectively, versus lane 7). The N6-(cyclopentyloxy) 
ATP, is in fact, a potent inhibitor of the I338G v-Src 
mutant (ICs0= 0.05 ~tM, data not shown). It is a poor 
inhibitor of the I338G mutant (IC50 = 80 p.M, data not 
shown). In terms of catalytic efficiency, however, the 
I338A mutant uses N6-(cyclopentyloxy) ATP with a cat- 
alytic efficiency higher than the I338G mutant. In our 
search for unnatural substrates of engineered enzymes, 
therefore, we have actually identified several ATP 
analogs which are highly selective inhibitors of the 
various mutant kinases [28]. 
In order to determine the catalytic rate constants for 
mutant v-Src phosphorylation we synthesized [y.3zp] 
N6-(benzyl) ATP, the best analog identified in the 
screen of our 12 A*TPs. The wild-type kinase GST-  
XD4 did not phosphorylate the IYGEFKKK peptide 
with [~,_3zp] N6.(benzyl) ATP, confirming our previous 
observation that this nucleotide analog is not a wild-type 
substrate. GST-XD4 (I338A) displays a kc~ t of 0.5 min -1 
with N6-(benzyl) ATP, 20 times higher than with 
N6-(cyclopentyl) ATP (0.025min-1; Table 1). The 
kcat/K m of GST-XD4 (I338G) with N6-(benzyl) ATP 
(4.0 × 104min -1M -1) is fourfold higher than with ATP 
(1.0 × 104rain -1M -1) and only fourfold less than wild- 
type kinase GST-XD4 with ATP (1.6 × 105 min -1 M-l). 
A 20-fold improvement of the catalytic efficiency of our 
mutant v-Src demonstrates the advantage of iterative 
mutagenesis and analog screening. Even more significant 
than the absolute increase in catalytic activity of the 
mutated kinase is the switch in the preferred substrate, 
from ATP to an A*TP. Our first generation v-Src mutant 
(V323A, I338A) preferentially utilizes ATP over N 6- 
(cyclopentyl) ATP (kcat:Kmratio6:l), whereas I338G 
v-Src preferentially uses N6-(benzyl) ATP over ATP 
(kcat:K m ratio 4:1). 
The key finding from our efforts to engineer v-Src to 
efficiently catalyze phosphotransfer reactions is that 
residue 338, a bulky residue in all known kinases (see 
Figure 1), limits the ability of v-Src to bind N6-substi - 
tuted A*TPs (Figure 8a,b). Mutation of this residue to 
alanine or glycine confers on v-Src the ability to accept 
N6-substituted A*TPs (Figure 8c). A screen of 12 candi- 
date A*TPs with various substituents at the N 6 position 
of ATP, identified N6-(benzyl) ATP as the best A*TP 
substrate. As protein kinases share a common protein 
fold, we reasoned that mutation of residues correspond- 
ing to 338 (in v-Src) might confer on other kinases the 
ability to accept N6-(benzyl) ATP (or another A*TP from 
our panel). 
Engineering Fyn, a Src family klnaee, to accept an A*TP 
The Src family of tyrosine kinases contains nine 
members: Src, Lck, Fyn, Lyn, Hck, Yes, Fgr, Blk and Yrk 
[5], which are involved in processes uch as lymphocyte 
development, platelet activation, and mast cell degranu- 
lation [29-31]. The amino acid at the position corre- 
sponding to 338 in v-Src is either threonine or isoleucine 
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Figure 8 
Surface representation f the ATP-binding pocket inthe Src family 
tyrosine kinase Hck and the proposed effect of enlarging the ATP- 
binding pocket to accommodate NS-(benzyl) ATP. (a) Wild-~pe Hck + 
AMP-PNP. The solvent-accessible surface of Hck within 7 Aof ATP is 
shown in white mesh, the surface of ATP is shown in blue mesh. The 
portion of Hck's solvent-accessible surface area formed by Thr338 
(corresponding to Ile338 in v-Src) is shown in red mesh. Atoms are 
colored the same as inFigure 1. Complementary packing of ATP into 
the wild-type Hck active site indicates the proximity f the N 6 amine of 
ATP to residue 338. (b) Wild-type Hck + NS-(benzyl) AMP-PNP. Model 
of the unfavorable packing of NS-(benzyl) ATP into the wild-type Hck 
active site, showing the steric clash between the benzyl ring of N 6 
(benzyl)ATP and the sidechain ofThr338. (¢) Mutant Hck (T338G) + 
NS-(benzyl) AMP-PNP. Model of the improved fit ofN6-(benzyl) ATP 
into the enlarged T338G mutant Hck ATP-binding pocket. The 
conformation of the N e benzyl ring was chosen by manually checking 
multiple rotamers of the N-C and C-Ph bonds in N6-(benzyl) ATP for 
steric clashes with the residues in the Hck active site using the program 
Insightll. The rotamer with the least steric clashes determined in this 
manner was then imported into the program GRASP (A. Nichols and B. 
Honig, Columbia University) to produce the surface maps. These 
figures were created using GRASP [41]. (We show Hck instead of Src 
because the structure of Src complexed to ATP is not available.) 
in all oncogenic or proto-oncogenic Src-family kinases. 
Mutation of Thr338 in c-Src to isoleucine is known to be 
sufficient for partial transformation of chicken embryo 
fibroblasts [12], as this single mutation is known to 
increase the specific activity of the c-Src kinase. Several 
Figure 9 
v-Sic isolates contain threonine at position 338, and thus 
isoleucine is not necessary to cause transformation of 
fibroblasts by v-Src [32]. The activating nature of the 
threonine to isoleucine mutation at this position could be 
the result of loss of a hydrogen bond between the 
A 
E= 
ATP 1 
Chemistry & Biology 
3 4 5 6 8 9 
A*TPs 11 12 
iST-Fyn (T339G) 
r GST-Fyn (T339A) 
GST-Fyn (WT) 
Fyn kinase 
(Thr339 mutants) 
Evaluation of the binding efficiency ofA*TPs 
to wild-type and mutant Fyn kinases. Binding 
efficiency was determined by inhibiting of [7" 
32p] ATP-dependent phosphorylation of the 
specific peptide IYGEFKKK by GST-Fyn, 
GST-Fyn (T339A) and GST-Fyn(T339G) 
with unlabelled ATP and A*TPs. Percentage 
inhibition was defined in the same manner as 
in Figure 3. 
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Table 2 
Kinetic constants for phosphorylation of the IYGEFKKK peptide by wild-type and mutant Fyn kinases. 
Nucleotide 
GST-Fyn (wild type) GST-Fyn ('F339A) GST-Fyn (T339G) 
kcat Km kcat/Km kcat Km kcat/Km kcat Km kcat/Km 
(min -1) (,uM) (min -1 M -1) (rain -1) (,u.M) (min -1 M -1) (min -1) (BM) (min -~ M -1) 
ATP 2.5+0.5 70+10 3.6x 104 0.8+0.2 90+_10 9.0+_103 0.5+_0.2 100+_10 5.0x  10 3 
N6-(benzyl) ATP > 2000 (Ki) 0.5 +_ 0.2 25 + 5 2.0 x 104 0.3 +_ 0.2 7 +_ 2 7.5 x 104 
The kinetic constants were determined in the same manner as in Table 1. 
hydroxyl group in Thr338 and bound ATP [11]. We 
chose Fyn as a test of the generality of our engineering 
method for several reasons: it is closely related to Src 
(sharing 85% sequence identity); it is a nontransforming 
kinase and thus has different regulatory domains which 
are not present in v-Src; and it is a critical kinase in multi- 
ple signaling pathways including the T cell receptor 
pathway, neuronal signaling, and the control of cell 
growth. The ability to identify Fyn's substrates in all rel- 
evant cellular contexts is an important goal. The first step 
in using our protein-based approach was to engineer Fyn 
to accept an A*TP. 
Full-length mouse Fyn tyrosine kinase was expressed as a 
GST-fusion protein in bacteria. It has a kca t of 2.5 min -1 
using the peptide substrate IYGEFKKK and ATP. Using 
our mutagcnesis of v-Src as a guide, we mutated position 
339 in Fyn from threonine to alanine or glycine; this 
allowed us to test how generally applicable our method is 
to kinases which contain a different residue than that 
found in v-Src. 
Both GST-Fyn (T339A) and GST-Fyn (T339G)show 
excellent inhibition by the same set of A*TPs which 
inhibit the corresponding alanine and glycine mutants in 
v-Src (Figure 9). In fact, both Fyn mutants catalyze 
peptide phosphorylation with N6-(benzyl) ATP efficiently 
(Table 2). The kca t/K m of both mutants with N6-(benzyl) 
ATP (2.0 × 104, 7.5 × 104 min -1 M -1 for the alanine and 
glycine mutants, respectively) is higher than with ATP 
(9.0 × 103, 5.0 × 103 min -1 M q for the alanine and glycine 
mutants, respectively) and comparable with the wild-type 
Fyn with ATP (3.6 x 104 min -1 M-l). The relative fficien- 
cies of the Fyn T339A, T339G mutants with N6-(benzyl) 
ATP versus ATP parallel those found with v-Src mutants, 
further confirming the functional and structural conserva- 
tion of the active site within the Src family of kinases. In 
fact, mutation of position 339 to alanine or glycine had a 
less detrimental effect in the overall catalytic efficiency 
when compared to wild-type Fyn than was found in the 
case of v-Src. This analysis uggests the Fyn mutant with 
A*TP is a nearly perfect mimic of wild-type Fyn with 
ATP, in terms of catalytic efficiency. 
S ign i f i cance  
Protein kinases play a central role in signal transduction. 
Nearly half the oncogenes that have been identified are 
protein kinases [33]. Identification of the in vivo sub- 
strates of protein kinases will provide a more detailed 
understanding of signaling cascades and also uncover 
important argets for rational drug design. Tremendous 
redundancy and overlapping substrate specificities among 
protein kinases has made it difficult to dissect he individ- 
ual signaling pathways by scanning sequences for a 
kinase's unique substrate motifs. We have developed a
protein engineering method to uniquely tag the direct sub- 
strates of a protein kinase of interest in the presence of 
many other cellular kinases. A detailed mutagenesis 
study of the prototypical tyrosine kinase, v-Src, is 
described here. We have created mutants of v-Src which 
can catalyze phosphorylation reactions with ATP  
analogs (A*TPs) that are not accepted by wild-type 
kinases, including v-Src itself. Specifically, we identified a
single mutation in the kinase domain which controls 
specificity for N6-substituted ATP  analogs; we also identi- 
fied an ATP  analog which is an efficient substrate for the 
mutant kinase. The mutant kinase-ATP analog pair dis- 
plays catalytic efficiency comparable to that of the wild- 
type kinase with the natural substrate ATP. With this 
v-Src mutant and ATP  analog, we can begin to identify 
the direct substrates of v-Src. Furthermore, the success- 
ful engineering of Fyn, another kinase for the Src family, 
demonstrates that this approach can be extended to other, 
non-oncogenic protein kinases. The new method for 
identifying direct protein kinase substrates will make it 
possible to dissect individual signaling pathways. 
Mater ia l s  and methods  
Synthesis of A TP analogs 
ATP analogs 1-12 were synthesized as described previously [18]. 
Pepfide synthesis 
The tyrosine kinase substrate peptide, IYGEFKKK, was synthesized on 
an Applied Biosystems AB431 A automatic solid-phase peptide synthe- 
sizer using a standard Fmoc peptide synthesis protocol [34,35] and 
WANG resin. Upon completion of peptide synthesis, the sidechain pro- 
tected (tBu for tyrosine and glutamic acid, Boc for lysine) peptide was 
cleaved from the resin using Reagent K [36]. Isolation via ether precipi- 
tation yielded peptides of sufficient purity (> 98O/o as determined via 
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reverse-phase high performance liquid chromatography [HPLC] and 
peptide sequencing) for the kinase reaction. 
Site-directed mutagenesis, protein expression and protein 
purification 
Overlap extension polyrnerase chain reaction (PCR) was used to make 
GST-XD4 (V323A) and GST-XD4 (1338A/G) [37]. Pfu polymerase 
(from Stragene) was used according to the manufacturer's protocol. 
Eight synthetic oligonucleotides were used to generate the GST-XD4 
v-Src and GST-Fyn mutant kinases: primer 1 (5'.'[-rTGGATCCATG- 
GGGAGTAGCAAGAGCAAG), primer 2 (5'-T'CrGAATTCCTACTCA- 
GCGACCTCCAACAC), primer 3 (5'-TGAGAAGCTGGCTCAACTGT- 
ACGCAG), primer 4 (5'-CTGCGTACAGTTGAGCCAGCTTCTCA), 
primer 5 (5'-CTACATCGTCGCTGAGTACATGAG), primer 6 (5'-CT- 
CATGTACTCAGCGACGATGTAG), primer ? (5'-CTACATCGTCGGG- 
GAGTACATGAG), primer 8 (5'-CTCATGTACTCCCCGACGATGTAG). 
Note that italics indicate restriction enzyme sites and bold indicates 
where mutations were induced. Primer 1 includes a BamH1 site and 
primer 2 has an EcoR1 site. Primers 3 and 4 contain the 1338G 
mutation. Primers 5 and 6 contain the 1338A mutation. Primers 7 and 8 
contain the 1338G mutation. The XD4 gene from YEp51-XD4 plasmid 
was amplified using primers 1 and primer 2. The PCR product was 
digested with BamH1 and EcoR1 and ligated into BamH1 and EcoRl- 
digested pGEX-KT and then transformed into the E. coil strain DH5c~. 
GST-XD4 (V323A) was made using primers 1, 2, 3 and 4 with the 
GST-XD4 (truncated v-Src) plasmid as the template, tn the first PCR, 
primers 1 and 4 were used to produce one fragment and primers 2 and 
4 were used to produce another fragment. In the second round of 
PCR, these two fragments were annealed and extended to form the full 
length GST-XD4 (V323A) gene. The PCR products were digested 
with BamH1 and EcoR1 and ligated into a similarly digested 
pGEX-KT. The resultant plasmid was transformed into the E. coil strain 
DH5o~. GST-XD4 (1338A) and GST-XD4 (1338G) were made in the 
same way except for the use of the corresponding internal primers (#5 
and #6 for 1338A, #7 and #8 for 1338G). GST-Fyn (T339A) and GST- 
Fyn ('F339G) were constructed using wild-type Fyn (murine Fyn in 
pSVTc, from Mike Cole, Princeton University) as the template. The 
primers corresponding to primers 1-6 used for GST-XD4 mutations 
are: primer 1' (5'-'ITFGGATCCATGGGCTGTGTGCAATGTAAG), 
primer 2' (5'.'I-FI'GAATTCTCACAGG'I-FTTCAACGGGCTG), primer 3' 
(5'-CAT'FI'ACATCGTCGCGGAGTACATGAG), primer 4' (5'-CTCAT- 
GTACTCCGCGACGATGTAAATG), primer 5' (5'-CAT'FTACATCGT- 
CGGGGAGTACATGAG), primer 6' (5'-CTCATGTACTCCCCGACG- 
ATGTAAATG). All mutants were sequenced over the entire coding 
region (Oligonucleotide sequencing and synthesis facility, Princeton 
University). Expression of kinases was carried out in DH5o~ as 
described by Xu et al. [38] with the exception that the cells were 
stored at 4"C overnight before centrifugation and lysis by French press 
(overnight storage is essential for producing highly active kinases). 
In vitro kinase peptide assay and autophosphorylation 
Assays of phosphorylation of the peptide substrate (IYGEFKKK) were 
carried out in triplicate at 22°C in a final volume of 30 pl buffered at 
pH 8.0 containing 50 mM Tris, 10 mM MgCI=, 1.6 mM glutathione, 
1 mg/ml BSA, 0.1 mM peptide with lO0nM of kinase, and 10pM 
[T32p]ATP (1000cpm/pmol; DuPont/NEN). For inhibition studies, 
100 pM unlabelled ATP or A*TPs (1-12) was added prior to the addi- 
tion of the enzyme. After 30 rain, reactions were quenched by spotting 
25pl of the reaction volume onto p81 phosphoceUulose disks 
(Whatman) and immersing in 250 ml of 10% acetic acid for > 30 min, 
followed by washing in 0.5% phosphoric acid and scintillation counting 
according to standard methods [39]. Similar assays were used to 
measure k~t and K M values for the GST-kinases. Kinase autophospho- 
rylation reactions were carried out in the presence of 50 pM [7-32P] ATP 
(5000 cpm/pmol) or [?.32p] Ne.(cyclopentyl) ATP (5000 cpm/pmol) at 
22"C for 1 h in a final volume of 30pl at pHS.0, 50raM Tris, 
10 mM MgCI 2 and 10 pmol of kinase. After adding 6 ILl 6X Laemmli gel 
loading buffer, proteins were separated by 12%o sodium dodecyl 
sulfate-polyacrylamide g l electrophoresis SDS-PAGE. The gel was 
soaked in 10%o acetic acid/10%0 isopropanol for 1 h, after which it was 
dried and exposed to film. 
" GFP-IYGEF Western blot assay 
The phosphorylatable sequence IYGEF was added to the carboxyl 
terminus of GFP [40] and expressed in DH5(~ cells as 6-His- 
GFP-IYGEF (G.Y., Y.L., S.D. Bixby, .I.D. Friedman and K.M.S., unpub- 
lished observations). Assays of GST-XD4 (1338A) and GST-XD4 
(1338G) phosphorylation of GFP-IYGEF were carried out at 22°C in 
a final volume of 30 p.I buffered at pH 8.0 containing 50 mM Tris, 
10 mM MgCI 2, 20 I~g/ml GFP-IYGEF and 50 ~M ATP or A*TPs. 
After 30 minutes, the reactions were quenched by adding 6p.I 6X 
Laemmli gel loading buffer. Proteins were separated using 12% 
SDS-PAGE. The gel was transferred to nitrocellulose paper (Schle- 
icher & Schuell). The blot was probed with the anti-phosphotyrosine 
antibody 4G10, and the bound antibody was detected via enhanced 
chemiluminescence after treatment with goat anti-mouse antibody 
(VWR Scientific 7101332). 
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